Consensus development conference on antipsychotic drugs and obesity and diabetes.
D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000145:classification / Q000627:therapeutic use; D015984:Causality; D015897:Comorbidity; D003430:Cross-Sectional Studies; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D016903:Drug Monitoring; D005500:Follow-Up Studies; D006801:Humans; D006937:Hypercholesterolemia / Q000139:chemically induced / Q000453:epidemiology; D015228:Hypertriglyceridemia / Q000139:chemically induced / Q000453:epidemiology; D009765:Obesity / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D011236:Prediabetic State / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control; D018570:Risk Assessment; D012559:Schizophrenia / Q000188:drug therapy* / Q000453:epidemiology
D014150:Antipsychotic Agents